Mergers and Acquisitions

Arranta Bio Signs Contract with MIT for Rapid mRNA Manufacturing Therapeutics

May 03, 2023

mRNA therapeutics are being researched to support the fight against rare diseases, infectious viruses, and cancers.

Sanofi Acquires Provention Bio

May 02, 2023

The acquisition was completed through the merger of a wholly owned subsidiary of Sanofi with and into Provention Bio.

GSK and BELLUS Health Enter Acquisition Agreement

April 20, 2023

GSK has reached an agreement to acquire late-stage biopharmaceutical company BELLUS Health.

Ginkgo Bioworks Acquires AAV Capsid Technology and Forms Partnership for Next-Gen CAR-T Cell Therapies

April 14, 2023

Ginkgo Bioworks has acquired StrideBio's AAV capsid discovery and engineering platform and has formed a partnership with WARF for development of next-gen cell therapies.

AnaBios Acquires Cell Systems, Expands Human Cell Portfolio for Drug Discovery

April 14, 2023

The acquisition of Cell Systems will bolster AnaBios’ portfolio of human tissue and cells for use in drug discovery.

Ingredion Announces Strategic Investments in India Expanding into High-Value Pharmaceutical Ingredients

March 27, 2023

Ingredion has completed two strategic investments in India with Amishi Drugs & Chemicals and Mannitab Pharma Specialties.

Sumitovant Acquires Myovant for $1.7 Billion

March 14, 2023

Sumitovant Bipharma has completed its acquisition of Myovant Sciences for approximately $1.7 billion.

Pharmapack Experts Predict Increased Packaging Consolidations in 2023

January 31, 2023

Pharmapack Europe experts expect smaller and medium European packaging companies to grow or be acquired.

Asimov and Center for Breakthrough Medicines Collaborate for Viral Vector Production

January 20, 2023

The partnership led to Asimov licensing its clonal GMP HEK293 suspension cell line to CBM for pre-clinical and clinical production of viral vectors for its clients.

Advaxis, Ayala Pharmaceuticals Complete Merger

January 19, 2023

The merged company will operate under the name Ayala Pharmaceuticals and will target the development and commercialization of Ayala’s lead program, AL102, for the treatment of desmoid tumors.